About Us Board of Directors

Howard J. Verrico, MD, Chairman of the Board, Founder and Secretary – Director
Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.

Géraldine Deliencourt-Godefroy, PhD, Chief Scientific Officer & Director
Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of France-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.

Christopher Hopton, Director
Mr. Christopher Hopton is Sirona Biochem’s Chief Financial Officer. He brings 15 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.

Michael Rogers, Director
Michael Rogers is an accomplished business executive with more than 25 years of progressive experience in the investment industry. Currently, Mr. Rogers is President of Palmer Rogers Encore Ventures, a company he co-founded with business partner and advertising leader, Frank Palmer. Prior to co-founding Palmer Rogers, Mr. Rogers held several leadership roles including Vice-President at Canaccord Capital and Senior Vice-President at Yorkton Securities. Previously, he also played a significant role in building the Bank of British Columbia to a major banking operation. In addition to his professional accomplishments, Mr. Rogers is deeply rooted in the local community and has served on the board of the Whistler Land Corporation, Whistler Resort Association and several charitable organizations.

Alex Sandro Marazzi, MD, Director
Dr. Marazzi is a family physician with certification in both Family and Emergency Medicine. He has been in family practice in Mission, British Columbia since 1997. He is also a part owner of a well established walk-in-clinic. Most recently he served as the Chief of the Emergency Department at Mission Memorial Hospital. Prior to practicing medicine in British Columbia, Dr. Marazzi was an Emergency Room physician for 7 years in Midland, Ontario. Dr. Marazzi earned his Bachelor of Pharmaceutical Sciences at UBC in 1985. While studying medicine he worked as a Hospital Pharmacist at Langley Memorial Hospital. He earned his Doctor of Medicine at UBC in 1989 and pursued an internship at Toronto East General Hospital.

Nigel Terrett, Director
Nigel Terret has held leadership roles at Excelleris Technologies, LifeLabs, MDS Inc. and MDS Diagnostics.  His several accomplishments in the life sciences sector include his role of Chairman of the Board at Excelleris Technologies, a medical information technology company, where he led the creation of the largest integrated patient and physician diagnostic database in Canada.  As Chief Strategic Officer of LifeLabs Inc., Nigel created innovative collaborative programs with health institutions, provincial governments and health providers to improve health care and reduce costs. As Senior Vice President and General Manager of Life Labs BC, Nigel was responsible for 900 operational staff, 90 branch locations and two state-of-the-art medical laboratories providing over 15 million medical results per year.  In this role, Nigel dramatically improved operational performance through Lean-Sigma methodologies.  As Chief Information Officer of MDS Diagnostics Inc., Nigel led the restructuring of information technology services that resulted in multi-million dollar savings.  As Vice-President IT at MDS Diagnostics, Nigel led a North American team that increased operating income by 50%. More recently, Nigel has provided strategic advisory services to the Biotech industry.

David Moore, Director
David joins the board of directors with significant biotech and big pharma experience. David is currently Chief Commercial Officer of Cempra, a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Prior to joining Cempra, David was Chief Business Officer of Ocera Therapeutics, a publicly traded clinical stage biotech focused in advanced liver disease. Prior to Ocera, he was Chief Business Officer of Tranzyme Pharma, a publicly traded clinical stage biotech and macrocyclic discovery chemistry company which David and the management team successfully merged with Ocera Therapeutics in July 2013. David has participated in several rounds of corporate financing, successfully negotiated multiple license deals for both clinical stage products and pre-clinical compounds in addition to the recent strategic merger process. David has an extensive commercial background having spent over 15 years developing and managing pharmaceutical commercial programs with the majority of that time spent with Ortho-McNeil and Janssen divisions of Johnson & Johnson. David received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.

TFChem0015

TFChem0015

Related Information

Product Development

While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.